The ghost of Exanta? The FDA briefing doc for Xarelto has been influenced, perhaps unduly, by the liver toxicity that was the undoing of Exanta.
Xarelto is already approved in the EU; if it does not make it through the FDA in one piece, it will be a bad harbinger for the entire drug/biotech industry, IMO.
Market Data 
Markets 
AI
